Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

NOCSAE warns athletes and parents not to rely solely on marketing, promotional materials

The National Operating Committee on Standards for Athletic Equipment issued a warning to athletes and parents of athletes to get the facts about football helmets and concussion protection – and not rely solely on marketing and promotional materials.

5 Feb 2011

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.

5 Feb 2011

ECR launches sleep aid product, Zolpimist Oral Spray in the US

NovaDel Pharma Inc. today announced that Zolpimist Oral Spray has been launched in the United States by ECR Pharmaceuticals, a subsidiary of Hi-Tech Pharmacal Co., Inc.. ECR Pharmaceuticals announced the immediate availability of Zolpimist Oral Spray, a novel delivery system of the most widely prescribed sleep aid in the US, zolpidem tartrate.

4 Feb 2011

Merck reports GAAP net income of $861 million for 2010

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses.

4 Feb 2011

New 'skin gun' treats burns with stem cells

A revolutionary new "skin gun" developed to treat burns could be the latest in a remarkable string of stem-cell breakthroughs poised to change the face of medicine, says Emerging Healthcare Solutions President and CEO Cindy Morrissey.

4 Feb 2011

Study: Pistachios may help reduce risk of heart disease

It's no coincidence that National Pistachio Day – February 26, 2011 – occurs during American Heart Month. Heart disease remains the leading cause of death in America, and promising nutrition research shows that pistachios are a heart healthy snack choice. In honor of American Heart Month, TheGreenNut.org is offering simple tips encouraging all Americans to go green for a healthy heart this February.

4 Feb 2011

Innovative Heart Attack Rapid Response Team for snow shoveling heart attacks

Loyola's innovative Heart Attack Rapid Response Team (HARRT) is on staff 24/7 to perform emergency surgery on patients who have experienced heart attacks from shoveling snow or other causes.

3 Feb 2011

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered the clinical study, SINGLE (ING114467), designed to support a new fixed-dose combination (FDC) therapy for the treatment of HIV.

3 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Eli Lilly and Company and Bristol-Myers Squibb Company announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC).

3 Feb 2011

New national initiative to increase heart attack awareness among women

A woman suffers a heart attack every minute in the United States. But according to a 2009 American Heart Association survey, only half of women said they would call 9-1-1 if they thought they were having a heart attack -- and many women did not even recognize several key symptoms. This combination has led to dangerous consequences.

2 Feb 2011

MAP Pharmaceuticals, Allergan collaborate for LEVADEX to treat acute migraine in adults

Allergan, and MAP Pharmaceuticals, today announced a collaboration within the United States for LEVADEX, a self-administered, orally inhaled therapy that has completed Phase III clinical development for the treatment of acute migraine in adults.

31 Jan 2011

Baxter launches OLIMEL emulsion for parenteral nutrition

Baxter International today announced the launch of OLIMEL emulsion for infusion in Canada at the American Society of Parenteral and Enteral Nutrition's Clinical Nutrition Week.

From Baxter International Inc. 31 Jan 2011

Loyola inaugurates clinic exclusively to treat children with headaches

Fortunately, in most cases the causes of childhood headaches are usually no cause for alarm, Schnitzler said. Children can get headaches from stress, anxiety, inadequate sleep, vision problems, caffeine or food sensitivities. To help pinpoint the cause, Loyola has opened a clinic that's exclusively devoted to treating children with headaches.

31 Jan 2011

Extreme morning sickness drug comes at a price

Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.

31 Jan 2011

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.

29 Jan 2011

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Genentech, a member of the Roche Group and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., today announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint.

28 Jan 2011

Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied.

28 Jan 2011

CSL Behring receives marketing approval for HAE drug Berinert in Israel

CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.

28 Jan 2011

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

Emergent BioSolutions Inc. today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP™) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is being developed in collaboration with Abbott.

25 Jan 2011